141 related articles for article (PubMed ID: 36130020)
1. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy.
Teijeira A; Garasa S; Luri-Rey C; de Andrea C; Gato M; Molina C; Kaisho T; Cirella A; Azpilikueta A; Wculek SK; Egea J; Olivera I; Rodriguez I; Rouzaut A; Verkhusha V; Valencia K; Sancho D; Berraondo P; Melero I
Cancer Res; 2022 Dec; 82(23):4373-4385. PubMed ID: 36130020
[TBL] [Abstract][Full Text] [Related]
2. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
[TBL] [Abstract][Full Text] [Related]
4. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8
Gardner A; de Mingo Pulido Á; Hänggi K; Bazargan S; Onimus A; Kasprzak A; Conejo-Garcia JR; Rejniak KA; Ruffell B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34987021
[TBL] [Abstract][Full Text] [Related]
5. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of renal injury by depleting cDC1 and by repurposing Flt3 inhibitor in anti-GBM disease.
Chen T; Cao Q; Wang R; Zheng G; Azmi F; Lee VW; Wang YM; Li H; Yu D; Rogers NM; Alexander SI; Harris DCH; Wang Y
Clin Immunol; 2023 May; 250():109295. PubMed ID: 36933629
[TBL] [Abstract][Full Text] [Related]
7. Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer.
Burrack AL; Schmiechen ZC; Patterson MT; Miller EA; Spartz EJ; Rollins MR; Raynor JF; Mitchell JS; Kaisho T; Fife BT; Stromnes IM
JCI Insight; 2022 Apr; 7(7):. PubMed ID: 35393950
[TBL] [Abstract]
